| HUMAN-TRIAL | evidence | Semaglutide Treatment in Type 1 Diabetes | Semaglutide | human-rct · n = 122 | — |
| HUMAN-TRIAL | evidence | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Semaglutide | human-rct · n = 349 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) | Semaglutide | Glycemic control · human-observational · n = 333 | — |
| HUMAN-TRIAL | evidence | Epicardial Cardiac Fat-CT (EPIC-CT) | Rybelsus | human-rct · n = 136 | — |
| HUMAN-TRIAL | evidence | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo | Semaglutide | human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Semaglutide | Kidney function · human-rct · n = 465 | — |
| HUMAN-TRIAL | evidence | The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes | Semaglutide | Glycemic control · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Treatment of GLP-1 for Diabetic Bariatric Patients | Semaglutide | Glycemic control · human-rct · n = 3 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 194 | — |
| HUMAN-TRIAL | evidence | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Semaglutide | Glycemic control · human-rct · n = 1250 | — |
| HUMAN-TRIAL | evidence | Novel Therapeutics and Endothelial Dysfunction in T1DM Patients | Ozempic | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 158 | — |
| HUMAN-TRIAL | evidence | A Study of a Novel Precision Medicine Approach For Obesity | Semaglutide | Weight & fat loss · human-rct · n = 135 | — |
| HUMAN-TRIAL | evidence | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Wegovy | n = 20 | — |
| HUMAN-TRIAL | evidence | Oral Semaglutide in Patients With Alzheimer's Disease | Rybelsus | Cognition & memory · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves | Semaglutide | Lipid & cardiovascular markers · human-rct · n = 160 | — |
| HUMAN-TRIAL | evidence | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | NN9535 | Glycemic control · human-rct · n = 415 | — |
| HUMAN-TRIAL | evidence | Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. | Ozempic | human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | Ozempic | human-rct · n = 61 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV | Semaglutide | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Treatment to Regress to Normoglycemia in Women with a Recent History of GDM | Ozempic | Glycemic control · human-rct · n = 102 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Semaglutide | Glycemic control · human-rct · n = 189 | — |
| HUMAN-TRIAL | evidence | Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults | Semaglutide | Weight & fat loss · n = 60 | — |
| HUMAN-TRIAL | evidence | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Semaglutide | Glycemic control · human-rct · n = 956 | — |
| HUMAN-TRIAL | evidence | A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 | Semaglutide | Weight & fat loss · human-rct · n = 88 | — |
| HUMAN-TRIAL | evidence | A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese | Semaglutide | Weight & fat loss · human-rct · n = 88 | — |
| HUMAN-TRIAL | evidence | A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) | Semaglutide | human-observational · n = 25664 | — |
| HUMAN-TRIAL | evidence | Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | Semaglutide | Glycemic control · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 9651 | — |
| HUMAN-TRIAL | evidence | A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea | Wegovy | Weight & fat loss · human-observational · n = 840 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 465 | — |
| HUMAN-TRIAL | evidence | Special Use - Results Surveillance on Long-term Use With Wegovy® | Wegovy | Weight & fat loss · human-observational · n = 1071 | — |
| HUMAN-TRIAL | evidence | Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects | Semaglutide | Glycemic control · human-rct · n = 161 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients | Semaglutide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. | Semaglutide | Glycemic control · n = 55 | — |
| HUMAN-TRIAL | evidence | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Semaglutide | Lipid & cardiovascular markers · human-rct · n = 7101 | — |
| HUMAN-TRIAL | evidence | Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes | Ozempic | Glycemic control · human-rct · n = 50 | — |
| HUMAN-TRIAL | evidence | A Study of Cardiovascular Events iN Diabetes Plus | Semaglutide | Glycemic control · human-rct · n = 21296 | — |
| HUMAN-TRIAL | evidence | Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice | Semaglutide | Weight & fat loss · human-observational · n = 70 | — |
| HUMAN-TRIAL | evidence | Latino Semaglutide Study | Semaglutide | Weight & fat loss · human-rct · n = 119 | — |
| HUMAN-TRIAL | evidence | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Ozempic | Weight & fat loss · human-rct · n = 125 | — |
| HUMAN-TRIAL | evidence | Genetics of the Acute Response to Oral Semaglutide | Rybelsus | Glycemic control · n = 1000 | — |
| HUMAN-TRIAL | evidence | Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. | Ozempic | Glycemic control · human-rct · n = 68 | — |
| HUMAN-TRIAL | evidence | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | Wegovy | Weight & fat loss · human-rct · n = 20 | — |
| HUMAN-TRIAL | evidence | Repurposing Semaglutide for the Treatment of Cocaine Use Disorder | Semaglutide | human-rct · n = 75 | — |
| HUMAN-TRIAL | evidence | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Ozempic | Weight & fat loss · human-rct · n = 164 | — |
| HUMAN-TRIAL | evidence | Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function | Semaglutide | human-rct · n = 22 | — |
| HUMAN-TRIAL | evidence | Semaglutide Use in Acute Pulmonary Embolism | Semaglutide | human-observational · n = 18 | — |
| HUMAN-TRIAL | evidence | A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity | Semaglutide | Weight & fat loss · human-rct · n = 29 | — |